The DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.
Platinum Resistance in Ovarian Cancer: Role of DNA Repair
Open accessAbstract
Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. It is initially responsive to cisplatin and carboplatin, two DNA damaging agents used in first line therapy. However, almost invariably, patients relapse with a tumor resistant to subsequent treatment with platinum containing drugs. Several mechanisms associated with the development of acquired drug resistance have been reported. Here we focused our attention on DNA repair mechanisms, which are fundamental for recognition and removal of platinum adducts and hence for the ability of these drugs to exert their activity. We analyzed the major DNA repair pathways potentially involved in drug resistance, detailing gene mutation, duplication or deletion as well as polymorphisms as potential biomarkers for drug resistance development. We dissected potential ways to overcome DNA repair-associated drug resistance thanks to the development of new combinations and/or drugs directly targeting DNA repair proteins or taking advantage of the vulnerability arising from DNA repair defects in EOCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Dai, C.-H., Li, J., Chen, P., Jiang, H., Wu, M. J., & Chen, Y. (2015) · Journal of Biomedical Science · doi:10.1186/s12929-015-0185-4 · Cited by 54
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature
Park, P. Y., Goldin, T., Chang, J., Markman, M., & Kundranda, M. N. (2015) · Case Reports in Oncology · doi:10.1159/000441772 · Cited by 5,273
ATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA Damage
Matsuoka, S., Ballif, B. A., Smogorzewska, A., McDonald, E. R., Hurov, K. E., Luo, J., Bakalarski, C. E., Zhao, Z., Solimini, N., Lerenthal, Y., et al. (2007) · Science · doi:10.1126/science.1140321 · Cited by 3,075
PARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 2,880
A living biobank of breast cancer organoids captures disease heterogeneity
Sachs, N., de Ligt, J., Kopper, O., Gogola, E., Bounova, G., Weeber, F., Balgobind, A. V., Wind, K., Gracanin, A., Begthel, H., et al. (2018) · Cell · doi:10.1016/j.cell.2017.11.010 · Cited by 1,973
Drost, J., & Clevers, H. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0007-6 · Cited by 1,790
The DNA damage response and cancer therapy
Lord, C. J., & Ashworth, A. (2012) · Nature · doi:10.1038/nature10760 · Cited by 1,649
Repair Pathway Choices and Consequences at the Double-Strand Break
Ceccaldi, R., Rondinelli, B., & D’Andrea, A. D. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.07.009 · Cited by 1,499
Schlacher, K., Christ, N., Siaud, N., Egashira, A., Wu, H., & Jasin, M. (2011) · Cell · doi:10.1016/j.cell.2011.03.041 · Cited by 1,255
Understanding nucleotide excision repair and its roles in cancer and ageing
Marteijn, J. A., Lans, H., Vermeulen, W., & Hoeijmakers, J. H. J. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3822 · Cited by 1,192 · cited 2×
“synthetizes the DNA sequence on the complementary strand [49,50].”
BackgroundDNA damage and the balance between survival and death in cancer biology
Roos, W. P., Thomas, A. D., & Kaina, B. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.2 · Cited by 1,189
State-of-the-art strategies for targeting the DNA damage response in cancer
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0114-z · Cited by 1,189
Dijkstra, K. K., Cattaneo, C. M., Weeber, F., Chalabi, M., van de Haar, J., Fanchi, L. F., Slagter, M., van der Velden, D. L., Kaing, S., Kelderman, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.009 · Cited by 1,135
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086
DNA repair dysregulation from cancer driver to therapeutic target
Curtin, N. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3399 · Cited by 1,051
DNA interstrand crosslink repair and cancer
Deans, A. J., & West, S. C. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3088 · Cited by 1,023
Resistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945
Replication fork stability confers chemoresistance in BRCA-deficient cells
Ray Chaudhuri, A., Callen, E., Ding, X., Gogola, E., Duarte, A. A., Lee, J.-E., Wong, N., Lafarga, V., Calvo, J. A., Panzarino, N. J., et al. (2016) · Nature · doi:10.1038/nature18325 · Cited by 930
The Dualistic Model of Ovarian Carcinogenesis
Kurman, R. J., & Shih, I.-M. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.11.011 · Cited by 923
Systems biology of cisplatin resistance: past, present and future
Galluzzi, L., Vitale, I., Michels, J., Brenner, C., Szabadkai, G., Harel-Bellan, A., Castedo, M., & Kroemer, G. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.428 · Cited by 782 · cited 1×
“In contrast to NER, defects of MMR are associated with resistance to both cisplatin and carboplatin [54–56], likely due to the ability of MMR proteins to detect the lesions and to activate apoptotic processes [57,58].”
BackgroundDNA repair, genome stability and cancer: a historical perspective
Jeggo, P. A., Pearl, L. H., & Carr, A. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.4 · Cited by 774
High grade serous ovarian carcinomas originate in the fallopian tube
Labidi-Galy, S. I., Papp, E., Hallberg, D., Niknafs, N., Adleff, V., Noe, M., Bhattacharya, R., Novak, M., Jones, S., Phallen, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00962-1 · Cited by 759
Homologous recombination and the repair of DNA double-strand breaks
Wright, W. D., Shah, S. S., & Heyer, W.-D. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.tm118.000372 · Cited by 713
Reinhardt, H. C., Aslanian, A. S., Lees, J. A., & Yaffe, M. B. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.024 · Cited by 596
Cisplatin resistance and opportunities for precision medicine
Amable, L. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.001 · Cited by 589
Organoid Models of Human Liver Cancers Derived from Tumor Needle Biopsies
Nuciforo, S., Fofana, I., Matter, M. S., Blumer, T., Calabrese, D., Boldanova, T., Piscuoglio, S., Wieland, S., Ringnalda, F., Schwank, G., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.001 · Cited by 473
The role of DNA mismatch repair in drug resistance
Nebel, S. (1998) · ETH Zürich Research Collection · doi:10.3929/ethz-a-001915508 · Cited by 461
Jiménez-Sánchez, A., Memon, D., Pourpe, S., Veeraraghavan, H., Li, Y., Vargas, H. A., Gill, M. B., Park, K. J., Zivanovic, O., Konner, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.025 · Cited by 458
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids
Hill, S. J., Decker, B., Roberts, E. A., Horowitz, N. S., Muto, M. G., Worley, M. J., Feltmate, C. M., Nucci, M. R., Swisher, E. M., Nguyen, H., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0474 · Cited by 452
Cruz, C., Castroviejo-Bermejo, M., Gutiérrez-Enríquez, S., Llop-Guevara, A., Ibrahim, Y. H., Gris-Oliver, A., Bonache, S., Morancho, B., Bruna, A., Rueda, O. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy099 · Cited by 433
The role of DNA mismatch repair in drug resistance.
Fink, D. A., Aebi, S. P., & Howell, S. B. (1998) · PubMed · Cited by 410
Kondrashova, O., Nguyen, M., Shield-Artin, K., Tinker, A. V., Teng, N. N. H., Harrell, M. I., Kuiper, M. J., Ho, G.-Y., Barker, H., Jasin, M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0419 · Cited by 407
Fanconi anaemia and cancer: an intricate relationship
Nalepa, G., & Clapp, D. W. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.116 · Cited by 389
ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer
Friboulet, L., Olaussen, K. A., Pignon, J.-P., Shepherd, F. A., Tsao, M.-S., Graziano, S., Kratzke, R., Douillard, J.-Y., Seymour, L., Pirker, R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214271 · Cited by 371
Nucleotide excision repair in humans
Spivak, G. (2015) · DNA Repair · doi:10.1016/j.dnarep.2015.09.003 · Cited by 354
How cells ensure correct repair of DNA double-strand breaks
Her, J., & Bunting, S. F. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.tm118.000371 · Cited by 304
Exploiting replicative stress to treat cancer
Dobbelstein, M., & Sørensen, C. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4553 · Cited by 302
Emerging common themes in regulation of PIKKs and PI3Ks
Lempiäinen, H., & Halazonetis, T. D. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.281 · Cited by 298
Drummond, J. T., Anthoney, A., Brown, R., & Modrich, P. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.33.19645 · Cited by 295
Vaisman, A., Varchenko, M., Umar, A., Kunkel, T. A., Risinger, J. I., Barrett, J. C., Hamilton, T. C., & Chaney, S. G. (1998) · PubMed · Cited by 294
Enhancing Tumor-Specific Uptake of the Anticancer Drug Cisplatin with a Copper Chelator
Ishida, S., McCormick, F., Smith-McCune, K., & Hanahan, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.011 · Cited by 288
Role of Glutathione in the Regulation of Cisplatin Resistance in Cancer Chemotherapy
Chen, H. H. W., & Kuo, M. T. (2010) · Metal-Based Drugs · doi:10.1155/2010/430939 · Cited by 287
Common mechanisms of PIKK regulation
Lovejoy, C. A., & Cortez, D. (2009) · DNA Repair · doi:10.1016/j.dnarep.2009.04.006 · Cited by 277 · cited 1×
“These are large serine/threonine kinases members of the phosphatidylinositol-3-kinase-like kinase family (PIKKs) and orchestrate a large network of cellular processes to maintain genomic integrity with distinct specificities and functions [40,41].”
BackgroundMukhopadhyay, A., Elattar, A., Cerbinskaite, A., Wilkinson, S. J., Drew, Y., Kyle, S., Los, G., Hostomsky, Z., Edmondson, R. J., & Curtin, N. J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2758 · Cited by 270
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
Johnson, N., Johnson, S. F., Yao, W., Li, Y.-C., Choi, Y.-E., Bernhardy, A. J., Wang, Y., Capelletti, M., Sarosiek, K. A., Moreau, L. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305170110 · Cited by 265
Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening
Verissimo, C. S., Overmeer, R. M., Ponsioen, B., Drost, J., Mertens, S., Verlaan-Klink, I., Gerwen, B. V., van der Ven, M., Wetering, M. V. D., Egan, D. A., et al. (2016) · eLife · doi:10.7554/elife.18489 · Cited by 263
Weigelt, B., Comino-Méndez, I., de Bruijn, I., Tian, L., Meisel, J. L., García-Murillas, I., Fribbens, C., Cutts, R., Martelotto, L. G., Ng, C. K. Y., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0544 · Cited by 263
Brown, R., Hirst, G. L., Gallagher, W. M., McIlwrath, A. J., Margison, G. P., van der Zee, A. G., & Anthoney, D. A. (1997) · Oncogene · doi:10.1038/sj.onc.1201167 · Cited by 243
Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.
Meijer, C., Mulder, N. H., Timmer‐Bosscha, H., Sluiter, W. J., Meersma, G. J., & de Vries, E. G. E. (1992) · PubMed · Cited by 216
Konecny, G. E., & Kristeleit, R. S. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.311 · Cited by 216
PARP inhibitors in ovarian cancer
Franzese, E., Centonze, S., Diana, A., Carlino, F., Guerrera, L. P., Di Napoli, M., De Vita, F., Pignata, S., Ciardiello, F., & Orditura, M. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.12.002 · Cited by 211
Yu, J. J., Lee, K. B., Mu, C., Li, Q., Abernathy, T. V., Bostick-Bruton, F., & Reed, E. (2000) · International Journal of Oncology · doi:10.3892/ijo.16.3.555 · Cited by 200
Okuno, S., Sato, H., Kuriyama-Matsumura, K., Tamba, M., Wang, H., Sohda, S., Hamada, H., Yoshikawa, H., Kondo, T., & Bannai, S. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600786 · Cited by 191
Srivastava, A. K., Han, C., Zhao, R., Cui, T., Dai, Y., Mao, C., Zhao, W., Zhang, X., Yu, J., & Wang, Q.-E. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421365112 · Cited by 188
Johnson, S. W., Laub, P. B., Beesley, J. S., Ozols, R. F., & Hamilton, T. C. (1997) · PubMed · Cited by 178
Patient-derived tumor organoids for prediction of cancer treatment response
Nagle, P. W., Plukker, J. T. M., Muijs, C. T., van Luijk, P., & Coppes, R. P. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.06.005 · Cited by 175
DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy
Carrassa, L., & Damia, G. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.013 · Cited by 170
Self-citationNucleotide excision repair: Why is it not used to predict response to platinum-based chemotherapy?
Bowden, N. A. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.01.005 · Cited by 169
Frey, M. K., & Pothuri, B. (2017) · Gynecologic Oncology Research and Practice · doi:10.1186/s40661-017-0039-8 · Cited by 151
Secondary mutations of BRCA1/2 and drug resistance
Dhillon, K. K., Swisher, E. M., & Taniguchi, T. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01840.x · Cited by 148
Öhrvik, H., Nose, Y., Wood, L. K., Kim, B.-E., Gleber, S.-C., Ralle, M., & Thiele, D. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311749110 · Cited by 147
Ceccaldi, R., O’Connor, K. W., Mouw, K. W., Li, A. Y., Matulonis, U. A., D’Andrea, A. D., & Konstantinopoulos, P. A. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2593 · Cited by 137
CDK12: an emerging therapeutic target for cancer
Lui, G. Y. L., Grandori, C., & Kemp, C. J. (2018) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205356 · Cited by 137
Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations
Ricci, F., Bizzaro, F., Cesca, M., Guffanti, F., Ganzinelli, M., Decio, A., Ghilardi, C., Perego, P., Fruscio, R., Buda, A. A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0274 · Cited by 135
Self-citationLatest clinical evidence and further development of PARP inhibitors in ovarian cancer
Mirza, M. R., Pignata, S., & Ledermann, J. A. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy174 · Cited by 134
Liu, J. F., Palakurthi, S., Zeng, Q., Zhou, S., Ivanova, E., Huang, W., Zervantonakis, I. K., Selfors, L. M., Shen, Y., Pritchard, C. C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1237 · Cited by 127
High‐throughput screening in colorectal cancer tissue‐originated spheroids
Kondo, J., Ekawa, T., Endo, H., Yamazaki, K., Tanaka, N., Kukita, Y., Okuyama, H., Okami, J., Imamura, F., Ohue, M., et al. (2018) · Cancer Science · doi:10.1111/cas.13843 · Cited by 124
Tumiati, M., Hietanen, S., Hynninen, J., Pietilä, E. A., Färkkilä, A., Kaipio, K., Roering, P., Huhtinen, K., Alkodsi, A., Li, Y., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3770 · Cited by 117
BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma
Beale, P. J., Rogers, P., Boxall, F. E., Sharp, S. Y., & Kèlland, L. R. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.0939 · Cited by 112
Hah, S. S., Stivers, K. M., White, R. D., & Henderson, P. T. (2006) · Chemical Research in Toxicology · doi:10.1021/tx060058c · Cited by 112
Kuhlmann, J. D., Wimberger, P., Bánkfalvi, Á., Keller, T., Schöler, S., Aktas, B., Buderath, P., Hauch, S., Otterbach, F., Kimmig, R., et al. (2014) · Clinical Chemistry · doi:10.1373/clinchem.2014.224808 · Cited by 111
Targeting DNA repair as a promising approach in cancer therapy
Damia, G. L. M., & D’Incalci, M. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.05.003 · Cited by 107
Self-citationRole of homologous recombination in trabectedin-induced DNA damage
Tavecchio, M., Simone, M., Erba, E., Chiolo, I., Liberi, G., Foiani, M., D’Incalci, M., & Damia, G. L. M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.01.003 · Cited by 98
Self-citationDai, Y., Jin, S., Li, X., & Wang, D. (2016) · Oncotarget · doi:10.18632/oncotarget.13817 · Cited by 98
Synthetic Lethality and Cancer – Penetrance as the Major Barrier
Ryan, C. J., Bajrami, I., & Lord, C. J. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.08.003 · Cited by 94
Unleashing Chk1 in cancer therapy
Carrassa, L., & Damia, G. L. M. (2011) · Cell Cycle · doi:10.4161/cc.10.13.16398 · Cited by 88
Self-citationImpaired DNA damage response — An Achilles' heel sensitizing cancer to chemotherapy and radiotherapy
Darżynkiewicz, Z., Traganos, F., & Włodkowic, D. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.05.032 · Cited by 86
Tomao, F., D’Incalci, M., Biagioli, E. C., Peccatori, F. A., & Colombo, N. (2017) · Cancer · doi:10.1002/cncr.30830 · Cited by 84
Haynes, B. M., Saadat, N., Myung, B., & Shekhar, M. P. V. (2014) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2014.11.005 · Cited by 79
Inhibition of the ERCC1–XPF structure-specific endonuclease to overcome cancer chemoresistance
McNeil, E. M., Astell, K. R., Ritchie, A., Shave, S., Houston, D. R., Bakrania, P., Jones, H. M., Khurana, P., Wallace, C., Chapman, T., et al. (2015) · DNA repair · doi:10.1016/j.dnarep.2015.04.002 · Cited by 79
A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers
George, E. M., Kim, H., Krepler, C., Wenz, B. M., Makvandi, M., Tanyi, J. L., Brown, E. J., Zhang, R., Brafford, P. A., Jean, S., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.89760 · Cited by 77
Mansouri, A., Zhang, Q. C., Ridgway, L. D., Tian, L., & Claret, F.-X. (2003) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504003108748410 · Cited by 76
Thigpen, T., Shingleton, H. M., Homesley, H. D., Lagasse, L. D., & Blessing, J. A. (1979) · PubMed · Cited by 74
Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies
Heo, E. J., Cho, Y., Cho, W. C. S., Hong, J. E., Jeon, H., Oh, D., Choi, Y., Song, S. Y., Choi, J., Bae, D., et al. (2017) · Cancer Research and Treatment · doi:10.4143/crt.2016.322 · Cited by 74
AlHilli, M. M., Becker, M. A., Weroha, S. J., Flatten, K. S., Hurley, R. M., Harrell, M. I., Oberg, A. L., Maurer, M. J., Hawthorne, K. M., Hou, X., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.08.328 · Cited by 73
Rossof, A. H., Rw, T., Stephens, R., Thigpen, T., Mk, S., Groppe, C. W., Hj, E., & Fisher, R. I. (1979) · PubMed · Cited by 68
Dual role of LRRC8A-containing transporters on cisplatin resistance in human ovarian cancer cells
Sørensen, B. H., Dam, C. S., Stürup, S., & Lambert, I. H. (2016) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2016.04.004 · Cited by 65
Xin (2009) · International Journal of Oncology · doi:10.3892/ijo_00000422 · Cited by 64
Bártková, J., Zemanova, M., & Bartek, J. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960611)66:6<779::aid-ijc12>3.0.co;2-z · Cited by 62
Friboulet, L., Postel-Vinay, S. C., Sourisseau, T., Adam, J., Stoclin, A., Ponsonnailles, F., Dorvault, N., Commo, F., Saulnier, P., Salomé‐Desnoulez, S., et al. (2013) · Cell Cycle · doi:10.4161/cc.26309 · Cited by 59
Bélanger, F., Fortier, E., Dubé, M., Lemay, J.-F., Buisson, R., Masson, J.-Y., Elsherbiny, A., Costantino, S., Carmona, E., Mes-Masson, A.-M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0618 · Cited by 58
A comparison of in vitro platinum-DNA adduct formation between carboplatin and cisplatin
Hongo, A., Shuji, S., Kosuke, A., & Kudo, T. (1994) · International Journal of Biochemistry · doi:10.1016/0020-711x(94)90072-8 · Cited by 57
Role and therapeutic potential of CDK12 in human cancers
Chilà, R., Guffanti, F., & Damia, G. L. M. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.09.003 · Cited by 54
Self-citationShah, M. M., Dobbin, Z. C., Nowsheen, S., Wielgos, M. E., Katre, A. A., Alvarez, R. D., Konstantinopoulos, P. A., Yang, E. S.-H., & Landen, C. N. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.05.009 · Cited by 53
Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells
Caiola, E., Salles, D. C., Frapolli, R., Lupi, M., Rotella, G., Ronchi, A., Garassino, M. C., Mattschas, N. A. L., Colavecchio, S., Broggini, M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5019 · Cited by 52
Self-citationMorin decreases galectin-3 expression and sensitizes ovarian cancer cells to cisplatin
Bieg, D., Sypniewski, D., Nowak, E., & Bednarek, I. A. (2018) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-018-4912-4 · Cited by 44
Li, T., Peng, J., Zeng, F., Zhang, K., Liu, J., Li, X., Ouyang, Q., Wang, G., Wang, L., Liu, Z., et al. (2017) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp202907 · Cited by 42
Rubatt, J. M., Darcy, K. M., Tian, C., Muggia, F. M., Dhir, R., Armstrong, D. K., Bookman, M. A., Niedernhofer, L. J., DeLoia, J. A., Birrer, M. J., et al. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.01.008 · Cited by 41
Expression of DNA repair genes in ovarian cancer samples: Biological and clinical considerations
Ganzinelli, M., Mariani, P., Cattaneo, D., Fossati, R., Fruscio, R., Corso, S., Ricci, F., Broggini, M., & Damia, G. L. M. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.11.029 · Cited by 40
Self-citationDifferential role of base excision repair proteins in mediating cisplatin cytotoxicity
Sawant, A., Floyd, A. M., Dangeti, M., Lei, W. H., Sobol, R. W., & Patrick, S. M. (2017) · DNA repair · doi:10.1016/j.dnarep.2017.01.002 · Cited by 40
PARP inhibitors for targeted treatment in ovarian cancer
Dizon, D. S. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32418-2 · Cited by 40
Zafar, M. K., Maddukuri, L., Ketkar, A. D., Penthala, N. R., Reed, M. R., Eddy, S., Crooks, P. A., & Eoff, R. L. (2018) · Biochemistry · doi:10.1021/acs.biochem.7b01176 · Cited by 37
Rodriguez, G. P., Song, J. B., & Crouse, G. F. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003682 · Cited by 33
Ricci, F., Fratelli, M., Guffanti, F., Porcu, L., Spriano, F., Dell’Anna, T., Fruscio, R., & Damia, G. L. M. (2016) · Oncotarget · doi:10.18632/oncotarget.7465 · Cited by 31
Self-citationZhao, M., Li, S., Zhou, L., Shen, Q., Zhu, H., & Zhu, X. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.12.018 · Cited by 31
A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agentsPreprint
Wilkes, D. C., Sailer, V., Xue, H., Cheng, H., Collins, C. C., Gleave, M. E., Wang, Y. Z., Demichelis, F., Beltran, H., Rubin, M. A., et al. (2017) · Molecular Case Studies · doi:10.1101/mcs.a001487 · Cited by 26
Guffanti, F., Fratelli, M., Ganzinelli, M., Bolis, M., Ricci, F., Bizzaro, F., Chilà, R., Sina, F. P., Fruscio, R., Lupia, M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25185 · Cited by 25
Self-citationDNA-damage response gene polymorphisms and therapeutic outcomes in ovarian cancer
Caiola, E., Porcu, L., Fruscio, R., Giuliani, D., Milani, R., Torri, V., Broggini, M., & Marabese, M. (2011) · The Pharmacogenomics Journal · doi:10.1038/tpj.2011.50 · Cited by 19
Self-citationGenetic markers for prediction of treatment outcomes in ovarian cancer
Caiola, E., Broggini, M., & Marabese, M. (2014) · The Pharmacogenomics Journal · doi:10.1038/tpj.2014.32 · Cited by 18
Self-citationRicci, F., Guffanti, F., Damia, G. L. M., & Broggini, M. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0662-3 · Cited by 15
Self-citationEffect of hOGG1 Over-Expression on Cisplatin Resistance in Esophageal Squamous Carcinoma Cells
Gao, D., Hu, J., Zhang, X., Gao, C., & Hong, J. (2013) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2012.1287 · Cited by 13
Srivastava, A. K., & Wang, Q.-E. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1043482 · Cited by 9
Patient‐derived organoids: New co‐clinical model to predict treatment response in cancer?
Castellón, E. A. (2018) · Oral Diseases · doi:10.1111/odi.12988 · Cited by 5
Cited by
Artificial intelligence (AI) and big data in cancer and precision oncology
Dlamini, Z., Francies, F. Z., Hull, R., & Marima, R. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.08.019 · Cited by 398
Understanding and targeting resistance mechanisms in cancer
Lei, Z., Tian, Q., Teng, Q., Wurpel, J. N. D., Zeng, L., Pan, Y., & Chen, Z. (2023) · MedComm · doi:10.1002/mco2.265 · Cited by 347
Natural and synthetic compounds in Ovarian Cancer: A focus on NRF2/KEAP1 pathway
Tossetta, G., & Marzioni, D. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106365 · Cited by 115
Effective sequential combined therapy with carboplatin and a CDC7 inhibitor in ovarian cancer
Li, J., Hu, H., He, J., Hu, Y., Liu, M., Cao, B., Chen, D., Ye, X., Zhang, J., Zhang, Z., et al. (2024) · Translational Oncology · doi:10.1016/j.tranon.2023.101825 · Cited by 4
Wei, R., Dai, H., Zhang, J., Shih, D. J. H., Liang, Y., Xiao, P., McGrail, D. J., & Lin, S.-Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22095008 · Cited by 4
Metadata
- Authors
- Damia, G., & Broggini, M.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2019-01-20
- Volume
- 11
- Issue
- 1
- Pages
- 119
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2908832432
- Cited by
- 298
- References
- 118
- FWCI
- 36.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.